ED95 of Liposomal Bupivacaine for Postoperative Local Infiltration Analgesia in Women Undergoing Cesarean Section: A Randomized Controlled Trial

This study indicated that the ED95 of liposomal bupivacaine for local infiltration analgesia following cesarean section was 206.1 mg (95% CI, 178.6, 262.5 mg). (registration number: ChiCTR2300076315).

Authors

Institutions

Publication Details

Journal
Drug Design Development and Therapy
Published
2026-02-01
DOI
https://doi.org/10.2147/dddt.s571871
Primary Topic
Anesthesia and Pain Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ED95 of Liposomal Bupivacaine for Postoperative Local Infiltration Analgesia in Women Undergoing Cesarean Section: A Randomized Controlled Trial

Jiafei Liu, Yang Zhang, Lin Liu, Wangping Zhang
Drug Design Development and Therapy
Anesthesia and Pain Management
article

ED95 of Liposomal Bupivacaine for Postoperative Local Infiltration Analgesia in Women Undergoing Cesarean Section: A Randomized Controlled Trial

Jiafei Liu, Yang Zhang, Lin Liu, Wangping Zhang
article en

Abstract

This study indicated that the ED95 of liposomal bupivacaine for local infiltration analgesia following cesarean section was 206.1 mg (95% CI, 178.6, 262.5 mg). (registration number: ChiCTR2300076315).

Drug Design Development and TherapyVol. Volume 20
Jiaxing University (CN), Ninghai County First Hospital (CN), First Hospital of Jiaxing (CN)
Gender equality
Openalex Percentile: Top 66%
Anesthesia and Pain Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.